Year in Review: 10 Specialty Drug Approvals to Know from 2018


This past year, several new drug approvals permeated the specialty pharmacy space, with an increasing number of products in the pipeline covering a range of specialty therapeutic areas.
 
While there were many notable approvals, we’ve rounded up a list of 10 newly-approved therapies to know from 2018.  
 
10. Erenumab-aooe (Aimovig, Amgen)
 
Erenumab-aooe was approved for the preventive treatment of migraine in adults, making it the first approved preventive migraine treatment of its kind. Given by once-monthly self injections, erenumab-aooe is part of a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks.
 
Read more here.  
 
9. Lanadelumab (Takhzyro, Shire)
 
The FDA approved lanadelumab, the first monoclonal antibody for the treatment of patients 12 years and older with types 1 and 2 hereditary angioedema (HAE), a rare hereditary disease. This new approval provides an additional treatment option for patients, which is significant because a Prime Therapeutics study found specialty drug costs were responsible for more than 97% of the total cost of care for HAE.
 
Read more here.  
 
8. Baricitinib (Olumiant, Eli Lilly)
 
Baricitinib, a 2-mg dose, once-daily oral drug, received approval for adults with moderately-to-severe active rheumatoid arthritis who had an inadequate response to 1 or more tumor necrosis factor inhibitor therapies. The treatment is indicated for use as a monotherapy or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs.
 
Read more here.  
 
7. Epidiolex (GW Pharmaceuticals)
 
Epidiolex is a novel cannabidiol treatment indicated to treat seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome, 2 rare and severe forms of epilepsy, in patients 2 years and older. It is the first FDA-approved medication that contains a purified drug substance derived from marijuana.
 
Read more here.
 
6. Tildrakizumab-asmn (Ilumya, Sun Pharmaceuticals)

Tildrakizumab-asmn, a novel biologic, received approval from the FDA for the treatment of moderate-to-severe plaque psoriasis among patients who are candidates for systemic therapy or photo therapy. It is indicated at a dose of 100 mg administered as a subcutaneous injection every 12 weeks, following initial doses at weeks 0 and 4.
 
Read more here.
 
5. Tofacitinib (Xeljanz, Pfizer)
 
Tofacitinib was the first Janus kinase inhibitor approved for the treatment of adult patients with moderately to severely active ulcerative colitis. Patients may take tofacitinib 10 mg twice-daily (BID) for at least 8 weeks, followed by tofacitinib 5 mg BID or 10 mg BID. With this approval, adults living with the disease now have an oral treatment option.
 
Read more here.  
 
4. Rituximab-abbs (Truxima, Celltrion and Teva)
 
Rituximab-abbs, a biosimilar to Rituxan (Genentech), was the first biosimilar approved for the treatment of adults with non-Hodgkin’s lymphoma. Rituximab-abbs is 1 of 7 biosimilars approved by the FDA in 2018.
 
Read more here.   
 
3. Emicizumab-kxwh (Hemlibra, Genentech)
 
Although initially approved in 2017 for adults and children with hemophilia A with factor VIII inhibitors, emicizumab-kxwh received approval in 2018 for hemophilia A without factor VIII inhibitors. This approval makes it the only treatment for both patient populations, while also providing an additional option other than intravenous infusions.
 
Read more here.  
 
2. Pegfilgrastim-jmdb (Fulphila, Mylan GmbH)
 
The FDA approved pegfilgrastim-jmdb as the first biosimilar to pegfilgrastim (Neulasta). The drug is used to decrease the chance of infection, with fever, associated with an abnormally low number of infection-fighting white blood cells in patients with non-bone marrow cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.
 
Read more here.
 
1. Fingolimod (Gilenya, Novartis)
 
Fingolimod received approval for the treatment of relapsing multiple sclerosis (MS) in pediatric patients aged 10 years and older, making it the first FDA-approved drug to treat MS in this population. The drug was initially approved in 2010 to treat adults with relapsing MS.
 
Read more here.
 
 



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Top news of the week from Specialty Pharmacy Times.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
An analysis of a quality improvement project at an oncology specialty pharmacy showed that pharmacist interventions can reduce financial toxicity for patients.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$